Eris Lifesciences Ltd.

₹1,327.6

-30.6 (-2.3%)

ERIS Share Price

Pharmaceuticals & Biotechnology

As on April 28, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 18,084 Cr

P/E Ratio51.39

Dividend Yield0.55 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	1,361.56	Bearish
10-DMA	1,397.86	Bearish
20-DMA	1,368.97	Bearish
50-DMA	1,356.66	Bearish
100-DMA	1,426.85	Bearish
200-DMA	1,552.23	Bearish

Historical Performance

1 Year

-10.7%

3 Years

110.3%

5 Years

118.3%

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	28,936	20,092	16,852	13,470	12,119
Total Expenditure	18,764	13,343	11,484	8,620	7,811
Other Income	184	238	112	261	87
Operating Profit	10,356	6,987	5,479	5,111	4,395
Interest	2,313	848	262	42	20
Depreciation	3,155	1,825	1,171	647	430
Profit Before Tax	4,889	4,313	4,046	4,422	3,945
Consolidated Net Profit	3,518	3,920	3,822	4,061	3,551
Adjusted EPS	26	29	28	30	26

Compounded Sales Growth

10 Years:39.6

5 Years:21.9

3 Years:16.5

TTM:7.6

Compounded Profit Growth

10 Years:31.6

5 Years:3.5

3 Years:-2.8

TTM:-2.1

Stock Price CAGR

10 Years:N/A

5 Years:17.1

3 Years:28.1

TTM:-9.4

Return on Equity

10 Years:9.7

5 Years:26.2

3 Years:28.1

last year:25.8

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	136	136	136	136	136
Total Reserves	28,306	25,676	21,796	18,928	15,589
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	21,010	9,793	7,300	-788	-1,091
Other Current Liabilities	5,308	9,002	1,901	358	291
Short Term Borrowings	3,966	13,113	550	---	---
Total Liabilities	68,623	68,104	34,719	21,127	17,028
Capital Work in Progress	667	191	214	240	---
Long Term Loans & Advances	883	698	253	359	259
Currents Investments	50	---	300	995	504
Short Term Loans and Advances	2,826	3,351	3,076	2,562	1,757
Total Current Assets	13,312	23,789	8,427	7,110	5,356
Total Assets	68,623	68,104	34,719	21,127	17,028
Adjusted Book Value	209	190	161	140	116

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 51.39, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 28.7%, indicating sustained price appreciation.
The stock carries a low beta of 0.3, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹10356 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹28936 million, indicating a large and established business.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 906335.3

No. of Shares: 683 (Approx)

Performance:-9.4%

P/L: ₹-93664.7

NIFTY Performance: -1.4%

1 day Top Gainers